- Home
- HRMY vs TENB Comparison
HRMY vs TENB Comparison
Compare HRMY & TENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HRMY | TENB |
|---|---|---|
| Founded | 2017 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.9B |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | HRMY | TENB |
|---|---|---|
| Price | $29.34 | $17.85 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 17 |
| Target Price | ★ $46.70 | $31.69 |
| AVG Volume (30 Days) | 605.9K | ★ 2.9M |
| Earning Date | 05-05-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.97 | 3.23 |
| EPS | ★ 2.71 | N/A |
| Revenue | $868,453,000.00 | ★ $999,405,000.00 |
| Revenue This Year | $19.75 | $9.37 |
| Revenue Next Year | $12.88 | $7.04 |
| P/E Ratio | $10.72 | ★ N/A |
| Revenue Growth | ★ 21.51 | 11.04 |
| 52 Week Low | $25.52 | $15.73 |
| 52 Week High | $40.87 | $35.69 |
Technical Indicators
Market Signals| Indicator | HRMY | TENB |
|---|---|---|
| Relative Strength Index (RSI) | 56.76 | 46.50 |
| Support Level | $25.92 | $17.28 |
| Resistance Level | $30.96 | $21.25 |
| Average True Range (ATR) | 0.82 | 1.10 |
| MACD | 0.42 | 0.04 |
| Stochastic Oscillator | 91.72 | 55.91 |
Price Performance
Historical ComparisonAbout HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About TENB Tenable Holdings Inc.
Founded in 2002, Tenable is a cybersecurity company that began providing vulnerability management solutions under its Nessus software. In recent years, Tenable has expanded its portfolio to provide a broader range of exposure management modules. Solutions include cloud security and compliance, active directory management, operational technology security and advanced vulnerability analytics. The Maryland-based company went public in 2018.